The relationship between lifestyle factors and outcome of treatment with TNFα inhibitors in axial spondyloarthritis – results from 14 European countries by Gareth T. Jones, Ovidiu Rotariu, Ross MacDonald, Brigitte Michelsen, Bente Glintborg, Irene van der Horst-Bruinsma, Bjorn Gudbjornsson, Arni Jon Geirsson, Heikki Relas, Pia Isomäki, Jakub Závada, Karel Pavelka, Ziga Rotar, Matija Tomšič, Michael J. Nissen, Adrian Ciurea, Catalin Codreanu, Johan K. Wallman, Eirik Klami Kristianslund, Simon Horskjaer Rasmussen, Lykke Midtbøll Ørnbjerg, Maria José Santos, Mikkel Østergaard, Merete Lund Hetland, Gary J. Macfarlane

“…Abstract Objectives To quantify the influence of lifestyle factors on tumour necrosis factor inhibitor (TNFi) treatment response, in axial spondyloarthritis (axSpA). …”
Get full text

Comparison of T cell response to vaccination in rheumatic patients treated with Janus kinase inhibitors and TNF inhibitors by Sebastian Hüper, Florian Eisele, Johannes Duell, Marc Schmalzing, Lea Nagler, Patrick Pascal Strunz, Matthias Froehlich, Jan Portegys, Michael Gernert

“…Abstract Background Janus kinase inhibitors (JAKi) represent a well-established therapeutic option for the treatment of autoimmune diseases. …”
Get full text

Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature by Saurabh Bhatia

“… Introduction: Apremilast, an oral phosphodiesterase-4 inhibitor, decreases the production of pro-inflammatory cytokines including tumour necrosis factor-α, interleukin-12/23, IL-12, IL-2, and interferon-γ; while upregulating the anti-inflammatory cytokine IL-10. …”
Get full text

Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature by Saurabh Bhatia

“… Introduction: Apremilast, an oral phosphodiesterase-4 inhibitor, decreases the production of pro-inflammatory cytokines including tumour necrosis factor-α, interleukin-12/23, IL-12, IL-2, and interferon-γ; while upregulating the anti-inflammatory cytokine IL-10. …”
Get full text